Table 2 Surgical outcomes
Postoperative evaluation | A1 (n = 12) | A2 (n = 12) | B1 (n = 16) | B2 (n = 12) |
|---|---|---|---|---|
Patients with definitive surgery—no. (%) | 11 (91.7) | 10 (83.3) | 14 (87.5) | 11 (91.6) |
Time from last neoadjuvant dose to definitive surgery—week, Median (IQR) | 4 (4–6) | 5 (4.8–5.3) | 5 (4–5) | 5 (4–5) |
Patients with canceled definitive surgery—no. (%) | 1 (8.3) | 2 (16.7) | 2 (12.5) | 1 (8.3) |
Disease progression | 1 (100) | 1 (50.0) | 0 (0) | 1 (100) |
Adverse event | 0 (0) | 1 (50.0) | 1 (50.0) | 0 (0) |
Other | 0 (0) | 0 (0) | 1 (50.0) | 0 (0) |
Of patients with delayed surgery, proportion no. (%) with delay of ≤ 2 weeks | 3 (27.2) | 0 (0) | 1 (7.1) | 1 (9.1) |
Surgical approach—no. (%) | ||||
Thoracotomy | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Minimally invasive | 11 (100) | 9 (90.0) | 13 (92.9) | 11 (100) |
Minimally invasive to thoracotomy | 0 (0) | 1 (10.0) | 1 (7.1) | 0 (0) |
Type of resection | ||||
Lobectomy | 10 (90.9) | 6 (60.0) | 12 (85.7) | 11 (100) |
Pneumonectomy | 0 (0) | 1 (10.0) | 1 (7.1) | 0 (0) |
Other | 1 (9.1) | 3 (30.0) | 1 (7.1) | 0 (0) |
Completeness of resection—no. (%) | ||||
R0 | 10 (90.9) | 10 (100) | 14 (100) | 11 (100) |
R1 | 1 (9.1) | 0 (0) | 0 (0) | 0 (0) |
Median length of hospital stay—days (IQR) | 9 (6–17) | 10 (8–12) | 8 (7–10) | 8 (8–10) |
Pathological lymph node evaluation | ||||
N0 | 4 (36.4) | 6 (60.0) | 8 (57.1) | 11 (100) |
N1 | 1 (9.1) | 3 (30.0) | 5 (35.7) | 0 (0) |
N2 | 5 (45.4) | 1 (10.0) | 1 (7.1) | 0 (0) |
N3 | 1 (9.1) | 0 (0) | 0 (0) | 0 (0) |
Pathological lymph node downstage | ||||
Yes | 4 (36.4) | 7 (70.0) | 6 (54.5) | 9 (100.0) |
No | 7 (63.6) | 3 (30.0) | 5 (45.5) | 0 (0) |
